BridgeBio Pharma Cash Flow from Investing Activities 2018-2023 | BBIO
BridgeBio Pharma annual/quarterly cash flow from investing activities history and growth rate from 2018 to 2023. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
- BridgeBio Pharma cash flow from investing activities for the quarter ending December 31, 2023 was $0.054B, a 88.08% decline year-over-year.
- BridgeBio Pharma cash flow from investing activities for the twelve months ending December 31, 2023 was $0.137B, a 89.6% decline year-over-year.
- BridgeBio Pharma annual cash flow from investing activities for 2023 was $0.054B, a 88.08% decline from 2022.
- BridgeBio Pharma annual cash flow from investing activities for 2022 was $0.453B, a 325.64% decline from 2021.
- BridgeBio Pharma annual cash flow from investing activities for 2021 was $-0.201B, a 278.97% increase from 2020.
BridgeBio Pharma Annual Cash Flow Investing
(Millions of US $) |
| 2023 |
$54 |
| 2022 |
$453 |
| 2021 |
$-201 |
| 2020 |
$-53 |
| 2019 |
$-217 |
| 2018 |
$-21 |
| 2017 |
$-0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$5.631B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
